InvestorsHub Logo
Followers 51
Posts 1681
Boards Moderated 0
Alias Born 02/15/2007

Re: None

Wednesday, 01/30/2013 12:50:28 AM

Wednesday, January 30, 2013 12:50:28 AM

Post# of 345953
Data from another pancreatic phase II trial presented at the 2013 Gastrointestinal Cancers Symposium. This one is for TH-302 (Threshold Pharmaceuticals),
same data as presented at the ESMO meeting on Sept 29, 2012. From the abstract:
A phase 3 study of TH-302 (340 mg/m ) in combination with G is planned with OS as the primary efficacy endpoint.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News